Vivos Therapeutics, Inc. Revenue, Remaining Performance Obligation, Percentage
Vivos Therapeutics, Inc. (VVOS) had Revenue, Remaining Performance Obligation, Percentage of 80.00% as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2026-08-14
- 2026-06-30: Revenue, Remaining Performance Obligation, Percentage 80.00%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2026-06-30 | 80.00% 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |